We serve Chemical Name:5-hydroxy-2-sulfanylbenzoic acid CAS:384339-80-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-hydroxy-2-sulfanylbenzoic acid
CAS.NO:384339-80-4
Synonyms:Benzoic acid,5-hydroxy-2-mercapto
Molecular Formula:C7H6O3S
Molecular Weight:170.18600
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:96.33000
Exact Mass:170.00400
LogP:1.37910
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Benzoic acid,5-hydroxy-2-mercapto chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzoic acid,5-hydroxy-2-mercapto physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzoic acid,5-hydroxy-2-mercapto Use and application,Benzoic acid,5-hydroxy-2-mercapto technical grade,usp/ep/jp grade.
Related News: China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement. 5-hydroxy-2-sulfanylbenzoic acid manufacturer The measure starts on February 4, according to South Korean Prime Minister Chung Sye-kyun. 5-hydroxy-2-sulfanylbenzoic acid supplier The measure starts on February 4, according to South Korean Prime Minister Chung Sye-kyun. 5-hydroxy-2-sulfanylbenzoic acid vendor Capacity: the bottleneck of business growth, expanding capacity and increasing utilization become a trend. Capacity is the core factor that determines the supply capacity of API companies. Insufficient capacity will cause companies to selectively complete orders and produce varieties, limiting the expansion of API products and market development. 5-hydroxy-2-sulfanylbenzoic acid factory We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries.